You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology

    SBC: Codagenix Inc.            Topic: NIAID

    DESCRIPTION provided by applicant The development of vaccine to combat Enterotoxigenic E coli ETEC is vital given the pathogenandapos s global impact on million individuals annually however an entirely new non conventional approach is needed Field studies have suggested that inert antigen based vaccines to combat ETEC have andquot essentially no efficacyandquot Therefore a vaccin ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an Antigen Capture Assay for Babesia microti

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. A New Non-Invasive Approach for Accessing Pulmonary Arterial Stiffness in Patients with Pulmonary Hypertension

    SBC: Arcus-Med LLC            Topic: NHLBI

    Pulmonary hypertensionPHis a disease affecting approximatelyof the general population that is characterized by abnormally elevated mean pulmonary artery pressuremPAPand pulmonary vascular resistancePVRIf left untreatedPH can ultimately lead to right heart failure and deathCurrent diagnostic approaches utilize invasive right heart catheterizationRHCto measure mPAP and PVREarly detection of PH leads ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Aminoglycosides with reduced ototoxicity via miRNA targeting

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ototoxici ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma

    SBC: Irex Pharma LLC            Topic: NIAID

    PROJECT SUMMARY Overmillion Americans have asthmawhich places an economic burden on the U Sof $billionAirway mucus overproduction is a hallmark of asthmaand the quantity and tenacity of mucus are increased during airway exacerbationsMucolytics degrade mucusbut do not reduce its productionAlthough corticosteroids and other anti inflammatory therapies indirectly decrease mucus productionand anti cho ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Identifying hereditary cancer patients in low-resource community cancer settings using an innovative informatics solution

    SBC: SGgenomics, Inc.            Topic: 101

    PROJECT SUMMARYHereditary cancer risk assessment in low resource community cancer settings is a signi cant unmet clinical needUnfortunatelymost community cancer clinics do not have adequate access to genetics expertise and patients are not systematically assessed for hereditary riskNew cost e ective and practical approaches are needed to assess and identify patients at risk for hereditary cancer c ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen

    SBC: Arrevus, Inc.            Topic: NIAID

    Multi drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Increasing Access and Developing Predictors for Colorectal Cancer Screening for Minority and Medicaid Clients

    SBC: Witness CARES, LLC            Topic: 102

    ABSTRACT African Americans havehigher incidence andhigher death rates from CRC than any other ethnic racial groupSimilarlylower socioeconomic statusSESis also associated with higher CRC incidence and mortalityBoth of these groups are overrepresented in Medicaid populationsScreening colonoscopy is a cost effective cancer prevention and control strategyleading to CRC preventione gremoval of precance ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Next generation HDAC inhibitors with superior potency, selectivity, and pharmacokinetic profiles for the treatment of liver ischemia-reperfusion injury

    SBC: Lydex Pharmaceuticals LLC            Topic: 300

    Hepatic ischemia reperfusion injuryIRIoccurs in many clinical situationssuch as traumahepatic surgerye gliver resection for tumor treatmentliver donation and transplantationshock and vascular diseasesHepatic I R causes severe liver injury and promotes inflammationleading to liver dysfunctionmultiple organ failure and deathIt also compromises long term outcomes after surgery and traumaCurrentlyno e ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government